BioLineRx (BLRX) to Release Quarterly Earnings on Wednesday

BioLineRx (NASDAQ:BLRX – Get Rating) is scheduled to be announcing its earnings results before the market opens on Wednesday, May 24th. Analysts expect the company to announce earnings of ($0.14) per share for the quarter.

BioLineRx (NASDAQ:BLRX – Get Rating) last posted its quarterly earnings results on Wednesday, March 22nd. The biotechnology company reported ($0.09) earnings per share for the quarter, topping the consensus estimate of ($0.14) by $0.05. On average, analysts expect BioLineRx to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

BioLineRx Stock Up 5.0 %

BLRX stock opened at $1.46 on Monday. The company has a debt-to-equity ratio of 0.17, a quick ratio of 4.87 and a current ratio of 4.87. The company has a market capitalization of $89.83 million, a price-to-earnings ratio of -2.92 and a beta of 1.89. BioLineRx has a fifty-two week low of $0.55 and a fifty-two week high of $1.98. The stock has a fifty day moving average of $1.05 and a 200-day moving average of $0.79.

Wall Street Analysts Forecast Growth

Several research analysts have recently weighed in on BLRX shares. StockNews.com started coverage on BioLineRx in a research note on Thursday. They set a “sell” rating for the company. HC Wainwright restated a “buy” rating on shares of BioLineRx in a research note on Wednesday, March 22nd.

Institutional Inflows and Outflows

Several large investors have recently added to or reduced their stakes in the stock. Envestnet Asset Management Inc. bought a new position in BioLineRx in the 1st quarter worth about $88,000. Renaissance Technologies LLC boosted its position in shares of BioLineRx by 278.0% during the 4th quarter. Renaissance Technologies LLC now owns 257,900 shares of the biotechnology company’s stock valued at $152,000 after acquiring an additional 189,678 shares during the last quarter. LPL Financial LLC boosted its position in shares of BioLineRx by 152.7% during the 4th quarter. LPL Financial LLC now owns 117,710 shares of the biotechnology company’s stock valued at $69,000 after acquiring an additional 71,134 shares during the last quarter. Finally, Atria Wealth Solutions Inc. bought a new stake in shares of BioLineRx during the 1st quarter valued at about $178,000. Institutional investors own 18.15% of the company’s stock.

BioLineRx Company Profile

(Get Rating)

BioLineRx Ltd. is a clinical stage biopharmaceutical company, which engages in the research and development of treatments that focus on cancer. Its product pipeline includes Motaxafortide (BL-8040), which is used for stem-cell mobilization, solid tumors, and acute myeloid lukemia; and AGI-134, which is an immunotherapy treatment used for multiple solid tumors.